Thus, targeting IL-17 immunologically can be an effective strategy to prevent acute respiratory distress syndrome (ARDS) in coronavirus disease 2019 (COVID-19) (Pacha et al., 2020). This evidence concerns the gene IL17A and glycogen storage disease VI.